Abstract
PrTX-I, a non-catalytic and myotoxic Lys49-PLA2 from Bothrops pirajai venom has been crystallized alone and in complex with bromophenacyl bromide (BPB), α-tocopherol and α-tocopherol acetate inhibitors. These crystals have shown to diffract X-rays between 2.34 and 1.65 Å resolution. All complexes crystals are isomorphous and belong to the space group P21 whereas native PrTX-I crystals belong to the P3121.
Keywords: Crystallization, X-ray crystallography, Lys49-phospholipase A2, Bothrops pirajai venom, myotoxity, pbromophenacyl bromide, p-BPB, α-tocopherol, vitamin E
Protein & Peptide Letters
Title: Preliminary X-Ray Crystallographic Studies of a Lys49-Phospholipase A2 Homologue from Bothrops pirajai Venom Complexed with p-Bromophenacyl Bromide and α-Tocopherol Inhibitors
Volume: 14 Issue: 7
Author(s): Juliana I. dos Santos, Daniela P. Marchi-Salvador, Carlos A.H. Fernandes, Lucas B. Silveira, Andreimar M. Soares and Marcos R.M. Fontes
Affiliation:
Keywords: Crystallization, X-ray crystallography, Lys49-phospholipase A2, Bothrops pirajai venom, myotoxity, pbromophenacyl bromide, p-BPB, α-tocopherol, vitamin E
Abstract: PrTX-I, a non-catalytic and myotoxic Lys49-PLA2 from Bothrops pirajai venom has been crystallized alone and in complex with bromophenacyl bromide (BPB), α-tocopherol and α-tocopherol acetate inhibitors. These crystals have shown to diffract X-rays between 2.34 and 1.65 Å resolution. All complexes crystals are isomorphous and belong to the space group P21 whereas native PrTX-I crystals belong to the P3121.
Export Options
About this article
Cite this article as:
Juliana I. dos Santos , Daniela P. Marchi-Salvador , Carlos A.H. Fernandes , Lucas B. Silveira , Andreimar M. Soares and Marcos R.M. Fontes , Preliminary X-Ray Crystallographic Studies of a Lys49-Phospholipase A2 Homologue from Bothrops pirajai Venom Complexed with p-Bromophenacyl Bromide and α-Tocopherol Inhibitors, Protein & Peptide Letters 2007; 14 (7) . https://dx.doi.org/10.2174/092986607781483796
DOI https://dx.doi.org/10.2174/092986607781483796 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Acute and Sub-acute Oral Toxicity Assessment of a Standardized Polyherbal Preparation POL-6 in Rats
The Natural Products Journal Gq protein-Coupled Receptors as Targets for Anesthetics
Current Pharmaceutical Design Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism Toxicokinetic Interaction Between Quetiapine and Antiretroviral Therapy Following Quetiapine Overdose
Drug Metabolism Letters Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Cycloaddition Methodology: A Useful Entry Towards Biologically Active Heterocycles
Current Organic Chemistry Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
Current Pharmaceutical Design Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Food Allergy
Current Pharmaceutical Design Continuous Renal Replacement Therapy in Children Post-Hematopoietic Stem Cell Transplantation: The Present and the Future
Current Stem Cell Research & Therapy